Coya Therapeutics (COYA) Competitors $6.36 +0.06 (+0.95%) Closing price 04:00 PM EasternExtended Trading$6.36 0.00 (-0.08%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock COYA vs. ATXS, UPXI, EOLS, AMRN, AUTL, FDMT, YMAB, LRMR, DBVT, and ETHZShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Astria Therapeutics (ATXS), Upexi (UPXI), Evolus (EOLS), Amarin (AMRN), Autolus Therapeutics (AUTL), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), Larimar Therapeutics (LRMR), DBV Technologies (DBVT), and Flag Ship Acquisition (ETHZ). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Its Competitors Astria Therapeutics Upexi Evolus Amarin Autolus Therapeutics 4D Molecular Therapeutics Y-mAbs Therapeutics Larimar Therapeutics DBV Technologies Flag Ship Acquisition Astria Therapeutics (NASDAQ:ATXS) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability. Which has more volatility and risk, ATXS or COYA? Astria Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Which has better valuation and earnings, ATXS or COYA? Coya Therapeutics has higher revenue and earnings than Astria Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$94.26M-$2.01-5.96Coya Therapeutics$3.55M29.97-$14.88M-$1.24-5.13 Is ATXS or COYA more profitable? Astria Therapeutics' return on equity of -56.39% beat Coya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -56.39% -36.08% Coya Therapeutics N/A -61.05%-53.61% Do analysts prefer ATXS or COYA? Astria Therapeutics currently has a consensus target price of $25.00, indicating a potential upside of 108.68%. Coya Therapeutics has a consensus target price of $16.20, indicating a potential upside of 154.72%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Coya Therapeutics is more favorable than Astria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media prefer ATXS or COYA? In the previous week, Astria Therapeutics had 24 more articles in the media than Coya Therapeutics. MarketBeat recorded 25 mentions for Astria Therapeutics and 1 mentions for Coya Therapeutics. Astria Therapeutics' average media sentiment score of 0.01 beat Coya Therapeutics' score of 0.00 indicating that Astria Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astria Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in ATXS or COYA? 99.0% of Astria Therapeutics shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 4.5% of Astria Therapeutics shares are held by company insiders. Comparatively, 12.0% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryCoya Therapeutics beats Astria Therapeutics on 8 of the 14 factors compared between the two stocks. Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.37M$3.40B$6.11B$10.51BDividend YieldN/A2.29%5.73%4.81%P/E Ratio-5.1322.4484.5227.09Price / Sales29.97484.29609.45131.82Price / CashN/A46.5937.1661.22Price / Book2.6810.4112.246.52Net Income-$14.88M-$52.47M$3.32B$276.75M7 Day Performance4.78%2.30%0.76%0.92%1 Month Performance17.56%14.45%8.03%4.20%1 Year Performance-22.63%12.90%71.13%37.86% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics2.5119 of 5 stars$6.36+1.0%$16.20+154.7%-21.2%$105.37M$3.55M-5.136Gap DownATXSAstria Therapeutics2.0326 of 5 stars$7.47-2.9%$29.50+294.9%+4.6%$421.57MN/A-3.7230Trending NewsAnalyst DowngradeUPXIUpexi2.4241 of 5 stars$7.05-8.4%$15.50+119.9%+121.7%$415.17M$15.81M0.00130Analyst ForecastEOLSEvolus3.9353 of 5 stars$6.26-2.6%$21.25+239.5%-63.9%$404.93M$277.94M-6.39170Analyst ForecastAMRNAmarin0.6621 of 5 stars$19.27-0.3%$12.00-37.7%+73.0%$398.56M$219.36M-5.25360Gap DownHigh Trading VolumeAUTLAutolus Therapeutics3.3017 of 5 stars$1.49-4.5%$9.12+512.1%-62.7%$396.55M$29.93M-1.77330FDMT4D Molecular Therapeutics3.1926 of 5 stars$8.32-1.0%$30.40+265.4%+16.5%$392.30M$33K-2.36120News CoveragePositive NewsAnalyst RevisionYMABY-mAbs Therapeutics1.3225 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150LRMRLarimar Therapeutics3.1996 of 5 stars$4.72-1.9%$16.71+254.1%-44.7%$390.71MN/A-3.0330High Trading VolumeDBVTDBV Technologies1.0754 of 5 stars$14.24+7.1%$14.75+3.6%+372.2%$390.11MN/A-2.9980Gap UpETHZFlag Ship AcquisitionN/A$2.33-8.6%N/AN/A$383.12MN/A-0.157News CoverageStock SplitGap DownHigh Trading Volume Related Companies and Tools Related Companies Astria Therapeutics Competitors Upexi Competitors Evolus Competitors Amarin Competitors Autolus Therapeutics Competitors 4D Molecular Therapeutics Competitors Y-mAbs Therapeutics Competitors Larimar Therapeutics Competitors DBV Technologies Competitors Flag Ship Acquisition Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COYA) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
